1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1630
  5. Art Unit 1633
  6. Examiner Vijayaraghavan

Examiner Vijayaraghavan Jagamya N

1633-VIJAYARAGHAVAN-JAGAMYA-N

Employment Information

Art Unit:1633 — Drug, bio-affecting and body treating compositions
Group:1630 — Stem cells and cell culture and Nucleic Acid related therapy
Classes: 435 — Chemistry: molecular biology and microbiology
424 — Drug, bio-affecting and body treating compositions
536 — Organic compounds -- part of the class 532-570 series
800 — Multicellular living organisms and unmodified parts thereof and related processes
Phone:(703) 756-5934
Email:None
Location:None
Title:Pat Examnr (Biology)
Service:2 years
Grade:GS-09

Grant Rate and Difficulty Ranking

3-Year Grant rate: 0% over 7 cases
Difficulty: Not enough data to rank
Difficulty Percentile:

With Examiner Vijayaraghavan, you have a 0% chance of getting an issued patent by 3 years after the first office action.

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Vijayaraghavan, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1633

Examiner Vijayaraghavan's grant rate is lower than that of Art Unit 1633 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Vijayaraghavan 1.2
Art Unit 1633 2.0

Interview Benefit

Grant Rate without Interview

Examiner Vijayaraghavan has granted 0 of 7 cases without any applicant-requested interviews for a grant rate of 0%.

Grant Rate with Interview

Examiner Vijayaraghavan has granted 0 of 0 cases with at least one applicant-requested interview for a grant rate of 0%.

Interview Benefit

With Examiner Vijayaraghavan, conducting an interview increases your chance of getting a patent granted by 100%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
17608860 Engineered T Cells Rejection information available with a Premium Stats subscription. See our pricing. Patented View
17797560 Synthetically Evolved Dna Constructs For Regulating Signal Peptide Performance As Well As Vectors, Host Cells And Recombinant Proteins Thereof Patented View
17992704 Genetic Modification Of Cytokine Inducible Sh2-Containing Protein (Cish) Gene Abandoned View
17618636 Cell Population Comprising Mesenchymal Cells, Pharmaceutical Composition Comprising The Same, And Method For Producing The Same Patented View
17909101 Compositions And Methods For The Treatment Of Metabolic Liver Disorders Patented View
17310064 Mesodermal Killer (Mk) Cell Patented View
17794206 Utilization Of Fgf Activators In Culture Media Abandoned View
17755434 Aav Vector Variants For Ocular Gene Delivery Patented View
17245619 Recombinant Adeno-Associated Virus Particle Purification Comprising An Affinity Purification Step Abandoned View
17779980 Gene Therapy For Neurodegenerative Disorders Patented View
17629034 Brain Organoid Manufacturing Method Abandoned View
17639249 Engineered T Cells And Methods Of Producing Thereof Abandoned View
17504822 Polynucleotide Encapsulation And Preservation Using Self-Assembling Membranes Patented View
17754807 Fibroblast-Based Immunotherapy Of Graves Disease Abandoned View
17774968 Isolation, Preservation, And Expansion Of Canine Umbilical Cord Mesenchymal Stromal Cells Patented View
17760333 Muscle-Specific Nucleic Acid Regulatory Elements And Methods And Use Thereof Patented View
17638007 Controlled Expression Of Viral Proteins Abandoned View
17290123 Graft And Use Thereof Abandoned View
17452104 Methods For Altering Polypeptide Expression Abandoned View
17756951 Compostions And Methods For Nucleic Acid Transfection Using Cationic Polymers And Stabilizers Abandoned View
17776575 Media Formulations And Methods For Producing Progenitor T Cells Abandoned View
17622838 Method For Constructing Hepatic Progenitor Cell-Like Cell Bank, Cell Lines Prepared Therefrom And Application Thereof Patented View
17618041 Method For Predicting Survival Following Streptococcus Iniae Infection Patented View
17624828 A Composition, A Kit And Use Thereof Abandoned View
17494601 Rna Replicon For Versatile And Efficient Gene Expression Patented View
17930652 Ultrapure Minivectors For Gene Therapy Abandoned View
17278358 Composition Intended For Increasing The Velocity Of Sperms Comprising Serotonin As Active Compound Abandoned View
17617468 Generation Of Neural Stem Cell Lines Derived From Human Pluripotent Stem Cells Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.